Ganeden continues Canadian expansion with new Health Canada approvals
August 17, 2017 By Bakers Journal
Cleveland, OH — Companies fortifying with Ganeden BC30 can now use additional probiotic claims on foods & beverages.
As a result of recent regulatory work, Ganeden has made advancements for the usage of its patented and shelf-stable probiotic strain, Ganeden BC30 (Bacillus coagulans GBI-30 6086) in Canada. Ganeden received a no objection letter from Health Canada that provided support for approved probiotic wording and allows Canadian companies fortifying with Ganeden BC30 to make additional health claims.
The no objection letter from Health Canada confirms that products fortified with Ganeden BC30 can make any of the general health claims that are allowed in the country’s probiotic monograph, and also provides opportunities for new gut flora language on packaging. This new approval makes it easier for companies to educate consumers on the benefits of Ganeden BC30 on their food and beverage product packaging.
“Canada has become a strong market for probiotic fortification in foods and beverages, and we are dedicated to advancing regulatory approvals and probiotic language both there and internationally,” said Dr. David Keller, vice president of scientific operations for Ganeden, in a press statement. “Our goal as a leader in the space is to make it as easy as possible for food and beverage manufacturers to fortify with a high-quality probiotic ingredient, and to also provide direction on probiotic-related health claims and educational content.”
The science-backed probiotic strain is known for its efficacy and stability, which allows it to survive most manufacturing processes, shelf life and gastric transit—opening up endless opportunities for fortification in foods and beverages where other probiotic strains are often unable to survive, reports the company in a news release.
Ganeden plans to continue its expansion and partnerships in the Canadian market, with multiple new probiotic products currently in development—many of which are expected to launch this year.
Print this page